← Back to Search

Virus Therapy

CVA21 / Ipilimumab for Uveal Melanoma (CLEVER Trial)

Phase 1
Waitlist Available
Led By Jose Lutzky, MD
Research Sponsored by Viralytics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.

Eligible Conditions
  • Uveal Melanoma
  • Liver Metastases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of treatment-related adverse events as assessed using the current NCI-CTCAE.
Secondary study objectives
Overall Response Rate

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CVA21 / IpilimumabExperimental Treatment2 Interventions
Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CVA21
2008
Completed Phase 2
~60
Ipilimumab
FDA approved

Find a Location

Who is running the clinical trial?

ViralyticsLead Sponsor
11 Previous Clinical Trials
295 Total Patients Enrolled
Jose Lutzky, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
3 Previous Clinical Trials
2,061 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top